Envoy Medical shares surge 17.48% intraday after first 10 patients complete six-month Acclaim trial with no adverse events.

Envoy Medical surged 17.48% intraday after announcing that the first 10 patients in its pivotal Acclaim cochlear implant trial completed six-month follow-ups with no serious adverse events. The milestone reinforces the device’s safety profile and aligns with the company’s timeline for FDA submission and commercialization. The CEO highlighted strengthened clinical confidence in the technology, which aims to provide discreet, full-time hearing without external hardware. This update followed recent trial expansion and new patent issuances, underscoring progress in Envoy’s development of its first-of-its-kind fully implanted cochlear implant. The FDA Breakthrough Device Designation (2019) and positive safety data likely drove investor optimism, as the trial advances toward regulatory approval and market entry.